Canadian L.P.’s Still Lead

Canadian cannabis L.P.’s are looking to be in a good position on the global stage. Marijuana’s momentum is rising worldwide, as many countries legalise and develop medical cannabis programs. Many expect the trend to continue in 2019, and Canadian producers are ready.

Many of the big pot companies are courting European investment dollars. L.P.’s have also signed export deals with European governments, acquired local businesses and opened production facilities in Europe.

The Canopy Spectrum companies

Canopy operates subsidiaries in Europe under its “Spectrum” subsdiary companies. Their goal is to simplify medical marijuana for physicians and patients. As such, Canopy’s overseas operations focus more education role than in North America.

According to an update the company provided this morning, their European subsidiaries are making headway in the U.K. and Poland.

U.K. lacks cannabis education

Following the U.K. November 1 decision to legalize cannabis for medical uses, Canopy’s aim is to educate patients and physicians on the uses of medical cannabis.

According to Dr. Mark Ware, Canopy’s Chief Medical Officer, “There
is significant real-world and clinical evidence supporting the safety and
effectiveness of cannabis-based medicinal products. However, due to the current
regulations and lack of education about medicinal cannabis among clinicians in
the U.K., there remain nconsiderable obstacles to patient access.”

He continued, “Spectrum U.K. has the expertise to simplify
the U.K. medicial cannabis landscape and ensure access to cannabis-based
medicial prdocuts for patients with unmet need.”

Spectrum Biomedical U.K.

Canopy’s U.K. subsidiary, Spectrum Biomedical U.K. was
formed via partnership with a research company based in Oxford, Beckley Canopy
Therapeutics.

Spectrum Cannabis Polska

The company’s Poland-based subsidiary, Spectrum Cannabis
Polska, also announced its first successful medical cannabis import this
morning. That country’s government has stated that 300,000 Polish patients could
qualify for medical marijuana access.

Organigram expands hemp supply and research

Because of the country’s regulatory atmosphere, Canadian company’s are also leading in agriculture technologies and genetic research.

Case in point, Organigram Holdings Inc. (TSXV: OGI.V) (OTC: OGRMF) announced an agreement with 1812 Hemp, an industrial hemp research company this morning. The company will get hemp supply containing CBD and access to genetic research and development.

“We are proud to work with other industry-leading companies and researchers to continue to explore the potential of hemp and cannabis plants and the efficiency with which we can deliver CBD to our customers,” Greg Engel, CEO Organigram.

Hemp supply to fuel CDB production

Organigram will get about 6,000 kg of dried hemp out of the deal. The company expects to begin extracting oil from that hemp early in 2019. It will also get access to future supply.

“Maximizing the CBD yield of hemp and cannabis means being able to meet increasing consumer demand for CBD while reducing overall production costs,” said Engel

We see the future CBD market in Canada and beyond to be an incredible opportunity” explains Engel. “CBD infused products will only grow in both medical and adult recreational channels, and we are focused on establishing the right relationships and processes now to fully take advantage of that opportunity.”

Is Organigram
a buy?

Although it’s unclear
how the acquisition will affect shareholder value, Organigram may be
undervalued for its growth prospects. The company’s production costs are still among
the lowest, and it has tremendous potential for growth.

Our picks

We ♥ weed stocks

Welcome to The Blunt Investor, where we take a daily dive into the lucrative marijuana industry. We believe that if you want to make better investments decisions, educate yourself. We hope you enjoy our opinions and thoughts.

Follow us

Newsletter

Want more news like this?

Email address:

Leave this field empty if you're human:

Don't worry, we don't spam

Disclaimer

The views, opinions and recommendations expressed on this website are those of the authors. Information contained in this website is for general information purposes only and is provided “as is”. This website should not be relied upon for making investment decisions and we always recommend that you consult a registered investment advisor before undertaking any investment.